Longer recurrence-free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus.

Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second-line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression-free survival rate remains short. We report one patient with mRCC who had a continuing response to temsirolimus.

Tubulocystic renal cell carcinoma in the left kidney: a case report.

Introduction: Tubulocystic renal carcinoma is a rare tumor and has been recently recognized as a neoplastic entity. We report a case of tubulocystic renal carcinoma in the left kidney and present a review of relevant literature.

Case Presentation: A 35-year-old Japanese woman visited our hospital with the chief complaint of left-sided back pain.